The Value of Rapid Antigen Testing
Title: The Value of Rapid Antigen Testing
Date: July 12, 2023
Time: 1 p.m. ET
Presenter: Amesh Adalja, MD
Preparing for the Next Tripledemic
The SARS-CoV-2, influenza (flu), and respiratory syncytial virus (RSV) tripledemic of the 2022–2023 U.S. respiratory season posed a challenge for both patients and the healthcare system. In this webinar, the presenter will discuss lessons learned and the value of using rapid antigen testing to detect these viruses.
As we progress toward the next respiratory season, healthcare facilities across the industry need to prepare to address simultaneous SARS-CoV-2, flu, and RSV outbreaks once again. By gaining access to low-cost, easy-to-use rapid antigen tests, clinicians can be better equipped to differentiate these viral infections so providers can offer more accurate diagnoses and treatment.
This webinar will help you:
- Explain the overall value of and differences between molecular and antigen testing
- Discuss the respiratory disease state and the recent tripledemic in the U.S.
- Describe the benefits of combination rapid antigen testing during respiratory seasons
Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.
Amesh Adalja, MD
Dr. Amesh Adalja works as an adjunct assistant professor at Johns Hopkins University, Carnegie Mellon University, and the University of Pittsburgh. He is also a senior scholar at the Johns Hopkins Center for Health Security and an affiliate of the Johns Hopkins Center for Global Health. Adalja is board certified in infectious disease, critical care, emergency, and internal medicine and actively practices in the Pittsburgh area. His other areas of focus include emerging infectious diseases, pandemic preparedness, and biosecurity.
Adalja has served on government panels tasked with developing guidelines for the treatment of plague, botulism, and anthrax in mass casualty settings and the system of care for infectious disease emergencies. He also served on a National Academies steering committee for diagnostic excellence.
Disclosure: Dr. Amesh Adalja received payment from Becton Dickinson & Co. for this presentation.